

## RATING ACTION COMMENTARY

# Fitch Affirms Stanford Health Care, CA's LT Ratings at 'AA' and CP Program at 'F1+'; Outlook Stable

Mon 13 May, 2024 - 11:57 AM ET

Fitch Ratings - Austin - 13 May 2024: Fitch Ratings has affirmed Stanford Health Care's (SHC) (fka Stanford Hospital and Clinics) Issuer Default Rating (IDR) at 'AA'. Fitch has also affirmed the 'AA' long-term rating on approximately \$2.4 billion of SHC's outstanding California Health Facilities Financing Authority (CHFFA) revenue bonds and self-issued taxable bond series.

Fitch has also affirmed the 'AA'/'F1+' rating on \$168.2 million in bonds (2008B series) that are supported by SHC's self-liquidity and the 'F1+' short-term rating on SHC's taxable and tax-exempt commercial paper (CP) facilities. The CP programs' 'F1+' short term rating is based on SHC's long term rating, and ample liquidity to service liquidity needs.

The Rating Outlook is Stable.

## RATING ACTIONS

ENTITY / DEBT ↕	RATING ↕	PRIOR ↕
Stanford Hospital and Clinics (CA)	LT IDR    AA Rating Outlook Stable	AA Rating Outlook Stable
	Affirmed	

Stanford Hospital and Clinics (CA) /General Revenues/1 LT	LT	AA Rating Outlook Stable	Affirmed	AA Rating Outlook Stable
---	----	--------------------------	----------	--------------------------

---

Stanford Hospital and Clinics (CA) /Self-Liquidity/1 ST	ST	F1+	Affirmed	F1+
---	----	-----	----------	-----

---

#### [VIEW ADDITIONAL RATING DETAILS](#)

SHC's 'AA' IDR and long-term bond ratings reflect its excellent operations and very strong financial profile, within the context of a midrange revenue defensibility and very strong operating risk profile assessment.

While some of SHC's capital-related ratios are only just slightly below Fitch's 'AA' rated medians and peers, the 'AA' rating continues to be supported by its extensive clinical reach in the greater San Francisco and Central Valley regions and as a nationwide/worldwide destination facility for very high-acuity services. SHC's strong market credit characteristics are balanced by a high degree of competition in its markets. Its highly favorable service area characteristics and very close relationship with Stanford University (rated 'AAA' by Fitch), further support the rating.

SHC's operating and operating EBITDA margins moderated only slightly in fiscal 2023 (audited results through Aug., 31, 2023), after a very strong fiscal 2022 operational gain, and are expected to remain consistently strong going forward. Capital needs are expected to remain high, but manageable, for the rating, assuming robust future capital spending in the coming years as the system addresses campus renovation/renewal efforts on its 300 Pasteur facility and addresses a few remaining seismic items.

The 'F1+' rating reflects SHC's long-term credit quality, together with its ability to cover the maximum potential liquidity demands presented by its taxable and tax-exempt CP (no amounts are currently outstanding on either program) and variable rate demand bond (VRDB) program including weekly mode and CP mode, with cash and highly liquid, highly rated investments.

#### **SECURITY**

Under a recently amended MTI, bonds will be secured by a security interest in all of the obligated group's gross receivables. The amended MTI changed the base of the annual rate

covenant to annual debt service (ADS) from maximum annual debt service (MADS). An annual debt service coverage below 1.1x requires a consultant but does not trigger an event of default.

## **KEY RATING DRIVERS**

### **Revenue Defensibility - 'bbb'**

#### ***Solid Position in Competitive Market with Favorable Demographics***

SHC has an excellent market position as the sole level I trauma center between San Francisco and San Jose, CA; an expansive service array of high acuity clinical services across the Central Valley and Northern California market; and a nationally/internationally recognized brand. Additionally, SHC is the primary adult academic teaching hospital for Stanford University. SHC's clinical strength is reflected in its healthy clinical volume growth and solid fundraising activity.

### **Operating Risk - 'aa'**

#### ***Consistently Positive Operating Margins; Additional and Robust Capital Spending Anticipated***

SHC's operating EBITDA and EBITDA margins were very strong at 11.6% and 13.2%, respectively, as of fiscal YE 2022 (Aug. 31) and remained strong in this most recent fiscal 2023 YE at 9.6% and 10.7%, respectively. SHC's sustained operations are driven in large part by sizable growth in clinical volumes and related net patient revenue. SHC avoided the worst of the sector-wide salary/wage/benefit expense increase and produced exceptional operating EBITDA and EBITDA margins the pandemic when significant portions of the sector struggled from an operational perspective.

Most recently, through the six-month interim period (unaudited) ended Feb., 29, 2024, SHC is still generating a very strong 8.5% operating margin and 12.5% operating EBITDA margin. Going forward, Fitch assumes that SHC can produce operating EBITDA margins in a similar range, but perhaps slightly more conservative than historical levels, at around an 9% operating EBITDA margin, but still very solid when compared to the sector.

Future capital needs remain manageable, with spending focused on the renewal of their 300 Pasteur inpatient buildings and remaining seismic needs.

## Financial Profile - 'aa'

### *Solid Balance Sheet Metrics Expected to Remain Consistent; Elevated Capital Spending Levels Anticipated*

SHC's financial profile continued to be stable and capital-related ratios remain resilient through Fitch's forward-looking scenario analysis. As of YTD Feb. 29, 2024, total adjusted debt of \$2.9 billion (which includes \$372 million in operating lease liability) is manageable against SHC's (as calculated by Fitch) over \$5.8 billion in unrestricted liquidity, equaling 270 days' cash on hand, and 198% cash to debt.

### **Asymmetric Additional Risk Considerations**

No asymmetric risk factors are associated with SHC's rating.

## **RATING SENSITIVITIES**

### **Factors that Could, Individually or Collectively, Lead to Negative Rating Action/Downgrade**

-- While not expected over the Outlook period, a significant additional borrowing that brings cash to adjusted debt to below 120% for a prolonged period could pressure the rating.

-- Should operating EBITDA margins drop below approximately 9% for a protracted period of time leading to a re-assessment of SHC's operating risk profile, might begin to pressure the current 'AA' rating.

### **Factors that Could, Individually or Collectively, Lead to Positive Rating Action/Upgrade**

-- Over a longer period, positive rating movement would require completion of major capital projects, and improvement in balance sheet and leverage metrics, such that cash and investments are sustained well in excess of 200% of debt and debt equivalents.

## **PROFILE**

SHC is the principal teaching affiliate of Stanford University's School of Medicine. SHC, together with Lucile Salter Packard Children's Hospital (rated AA-), operates clinical settings through which the School of Medicine educates medical and graduate students, trains residents and clinical fellows, supports faculty and community clinicians and conducts medical and biological sciences research. SHC's close relationship with Stanford

University and its School of Medicine generates certain reputational and clinical benefits that are unique in the service area and imperative for on-going recruitment purposes.

SHC operates a 619 licensed-bed tertiary, quaternary and specialty hospital, as well as the primary, specialty and subspecialty clinics in which the medical faculty of the School of Medicine provide clinical services. SHC is also the sole corporate member of the 242 licensed-bed Stanford Health Care Tri-Valley, located in the East Bay. SHC's total revenues in fiscal 2023 were approximately \$7.9 billion.

The main Stanford Hospital is located on the campus of Stanford University, adjacent to the School of Medicine in Palo Alto, CA.

### **Sources of Information**

In addition to the sources of information identified in Fitch's applicable criteria specified below, this action was informed by information from Lumesis.

### **REFERENCES FOR SUBSTANTIALLY MATERIAL SOURCE CITED AS KEY DRIVER OF RATING**

The principal sources of information used in the analysis are described in the Applicable Criteria.

### **ESG CONSIDERATIONS**

The highest level of ESG credit relevance is a score of '3', unless otherwise disclosed in this section. A score of '3' means ESG issues are credit-neutral or have only a minimal credit impact on the entity, either due to their nature or the way in which they are being managed by the entity. Fitch's ESG Relevance Scores are not inputs in the rating process; they are an observation on the relevance and materiality of ESG factors in the rating decision. For more information on Fitch's ESG Relevance Scores, visit

[www.fitchratings.com/topics/esg/products#esg-relevance-scores](http://www.fitchratings.com/topics/esg/products#esg-relevance-scores).

### **FITCH RATINGS ANALYSTS**

**Kevin Holloran**

Senior Director

Primary Rating Analyst

+1 512 813 5700

kevin.holloran@fitchratings.com

Fitch Ratings, Inc.  
2600 Via Fortuna, Suite 330 Austin, TX 78746

**Michael Burger**

Director

Secondary Rating Analyst

+1 415 796 9960

michael.burger@fitchratings.com

**Eva Thein**

Senior Director

Committee Chairperson

+1 212 908 0674

eva.thein@fitchratings.com

**MEDIA CONTACTS**

**Sandro Scenga**

New York

+1 212 908 0278

sandro.scenga@thefitchgroup.com

Additional information is available on [www.fitchratings.com](http://www.fitchratings.com)

**PARTICIPATION STATUS**

The rated entity (and/or its agents) or, in the case of structured finance, one or more of the transaction parties participated in the rating process except that the following issuer(s), if any, did not participate in the rating process, or provide additional information, beyond the issuer's available public disclosure.

**APPLICABLE CRITERIA**

[U.S. Not-For-Profit Hospitals and Health Systems Rating Criteria \(pub. 18 Nov 2020\)](#)  
(including rating assumption sensitivity)

[U.S. Public Sector, Revenue-Supported Entities Rating Criteria \(pub. 12 Jan 2024\)](#) (including rating assumption sensitivity)

**APPLICABLE MODELS**

Numbers in parentheses accompanying applicable model(s) contain hyperlinks to criteria providing description of model(s).

Portfolio Analysis Model (PAM), v2.0.0 (1)

## **ADDITIONAL DISCLOSURES**

[Dodd-Frank Rating Information Disclosure Form](#)

[Solicitation Status](#)

[Endorsement Policy](#)

## **ENDORSEMENT STATUS**

Stanford Health Care (CA)

EU Endorsed, UK Endorsed

## **DISCLAIMER & DISCLOSURES**

All Fitch Ratings (Fitch) credit ratings are subject to certain limitations and disclaimers.

Please read these limitations and disclaimers by following this link:

<https://www.fitchratings.com/understandingcreditratings>. In addition, the following <https://www.fitchratings.com/rating-definitions-document> details Fitch's rating definitions for each rating scale and rating categories, including definitions relating to default. ESMA and the FCA are required to publish historical default rates in a central repository in accordance with Articles 11(2) of Regulation (EC) No 1060/2009 of the European Parliament and of the Council of 16 September 2009 and The Credit Rating Agencies (Amendment etc.) (EU Exit) Regulations 2019 respectively.

Published ratings, criteria, and methodologies are available from this site at all times. Fitch's code of conduct, confidentiality, conflicts of interest, affiliate firewall, compliance, and other relevant policies and procedures are also available from the Code of Conduct section of this site. Directors and shareholders' relevant interests are available at

<https://www.fitchratings.com/site/regulatory>. Fitch may have provided another permissible or ancillary service to the rated entity or its related third parties. Details of permissible or ancillary service(s) for which the lead analyst is based in an ESMA- or FCA-registered Fitch Ratings company (or branch of such a company) can be found on the entity summary page for this issuer on the Fitch Ratings website.

In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable

investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third-party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed. Fitch Ratings makes routine, commonly-accepted adjustments to reported financial data in accordance with the relevant criteria and/or industry standards to provide financial metric consistency for entities in the same sector or asset class.

The complete span of best- and worst-case scenario credit ratings for all rating categories ranges from 'AAA' to 'D'. Fitch also provides information on best-case rating upgrade scenarios and worst-case rating downgrade scenarios (defined as the 99th percentile of rating transitions, measured in each direction) for international credit ratings, based on historical performance. A simple average across asset classes presents best-case upgrades of 4 notches and worst-case downgrades of 8 notches at the 99th percentile. For more details on sector-specific best- and worst-case scenario credit ratings, please see [Best- and Worst-Case Measures](#) under the Rating Performance page on Fitch's website.



The information in this report is provided “as is” without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US\$1,000 to US\$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US\$10,000 to US\$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.

For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001. Fitch Ratings, Inc. is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (the “NRSRO”). While certain of the NRSRO's credit rating subsidiaries are listed on Item 3 of

Form NRSRO and as such are authorized to issue credit ratings on behalf of the NRSRO (see <https://www.fitchratings.com/site/regulatory>), other credit rating subsidiaries are not listed on Form NRSRO (the “non-NRSROs”) and therefore credit ratings issued by those subsidiaries are not issued on behalf of the NRSRO. However, non-NRSRO personnel may participate in determining credit ratings issued by or on behalf of the NRSRO.

dv01, a Fitch Solutions company, and an affiliate of Fitch Ratings, may from time to time serve as loan data agent on certain structured finance transactions rated by Fitch Ratings.

Copyright © 2024 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved.

[READ LESS](#)

## **SOLICITATION STATUS**

The ratings above were solicited and assigned or maintained by Fitch at the request of the rated entity/issuer or a related third party. Any exceptions follow below.

## **ENDORSEMENT POLICY**

Fitch’s international credit ratings produced outside the EU or the UK, as the case may be, are endorsed for use by regulated entities within the EU or the UK, respectively, for regulatory purposes, pursuant to the terms of the EU CRA Regulation or the UK Credit Rating Agencies (Amendment etc.) (EU Exit) Regulations 2019, as the case may be. Fitch’s approach to endorsement in the EU and the UK can be found on Fitch’s [Regulatory Affairs](#) page on Fitch’s website. The endorsement status of international credit ratings is provided within the entity summary page for each rated entity and in the transaction detail pages for structured finance transactions on the Fitch website. These disclosures are updated on a daily basis.